The agreement will give Winhealth rights to Ravicti in China and several other Asia-Pacific countries
Hongkong-based WinHealth Pharma Group Co, and Immedica Pharma, have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti (glycerol phenylbutyrate), in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.
Ravicti is in Europe and North America indicated for the treatment of urea cycle disorders (UCD), and under the announced partnership, WinHealth is granted a license to register and commercialise the product in UCD in the countries of the specified territory.
“It is with great pleasure that we announce this partnership with WinHealth, under which we will be able to make Ravicti available to UCD patients also in this part of the world. It also strengthens Immedica’s geographical footprint, by introducing yet another rare disease collaboration to our network”, says Anders Edvell, CEO, Immedica.
Torreya acted as a financial advisor to Immedica for this transaction.
Jack Wang, Chairman and CEO, Winhealth, comments, “Urea Cycle Disorder represents a severely underserved medical need in China, resulting in severe neurocognitive decline, coma or even death, if left untreated. We are excited to partner up with Immedica and look forward to bringing Ravicti, an innovative therapeutic approved both in Europe and the US, to the patients suffering from UCD in China and adjacent countries.”
